Introduction: A New Direction for Clinical Trial Regulatory Reviews
Clinical trial sponsors working across multiple markets must navigate different regulatory requirements, submission procedures and review timelines. When a clinical trial protocol has already undergone assessment by one regulatory authority, repeating parts of the assessment in another jurisdiction may create additional work and extend preparation timelines.
The new pilot between Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) introduces a structured approach to addressing this challenge. Announced on 21 September 2026, the six-month initiative is designed to explore how PMDA’s completed assessment of an eligible clinical trial protocol can support NPRA’s review of the corresponding Clinical Trial Import Licence (CTIL) or Clinical Trial Exemption (CTX) application.
For sponsors, clinical trial regulatory reliance in Japan and Malaysia could offer a more efficient route for eligible applications. However, the pilot has specific eligibility criteria, documentation requirements and regulatory oversight provisions that sponsors must understand before planning a submission.
What is Clinical Trial Regulatory Reliance?
Clinical trial regulatory reliance is an approach in which one regulatory authority uses or gives appropriate weight to the assessment work of another trusted authority when making its own regulatory decision. Instead of duplicating all assessment activities, the relying authority can consider the existing regulatory assessment alongside its own requirements and responsibilities.
Reliance does not mean automatic approval. The authority receiving the application retains responsibility for its decision and must ensure that applicable national requirements and public health safeguards are maintained.
The World Health Organization’s Good Reliance Practices support this approach to make better use of regulatory expertise and resources while maintaining independent regulatory decision-making.
Overview of the Japan–Malaysia Regulatory Reliance Pilot
The NPRA–PMDA pilot is a time-limited initiative focused on eligible clinical trial applications in Malaysia that have already completed the relevant assessment process in Japan. According to NPRA’s official announcement, the initiative is intended to improve regulatory efficiency, support timely access to investigational products and evaluate the practical value of reliance in clinical trial reviews.
- The Role of PMDA and NPRA
The two authorities have distinct responsibilities within the pathway:- PMDA, Japan: Conducts the relevant clinical trial notification assessment in Japan and provides assessment inputs through the reliance process.
- NPRA, Malaysia: Receives the Malaysian CTIL/CTX application, initiates the formal request to PMDA and retains responsibility for its regulatory review and decision.
This arrangement allows NPRA to consider PMDA’s assessment without transferring its regulatory authority to Japan.
- Objectives and Scope of the Pilot
The pilot aims to test whether regulatory reliance can reduce duplicated assessment work while preserving appropriate regulatory oversight.
Its stated targets include:- Duration: Six months, targeted from October 2026 to March 2027.
- Participation: Five or more clinical trial protocols.
Product and study types: At least three different types, with examples including biologics, new chemical entities (NCEs), generic drugs, herbal products and first-in-human (FIH) trials.
Assessment basis: The specific clinical trial protocol must have completed PMDA’s standard 30-day assessment process.
These are pilot targets and scope parameters, not evidence that the pathway has already achieved its intended outcomes.
- Pilot Timeline and Implementation Status
The pilot was announced on 21 September 2026, with implementation targeted for October 2026 through March 2027.
The six-month period is intended to generate practical evidence on the pathway’s operation, including its review timelines and suitability across different product or study types. NPRA has indicated that the findings will help inform future regulatory guidance for CTIL/CTX applications and product registrations using the NPRA–PMDA reliance framework.
As the pilot progresses, sponsors should confirm the latest requirements directly with NPRA rather than assume that the pilot arrangements will remain unchanged or become a permanent pathway.
How Does the PMDA–NPRA Reliance Pathway Work?
The pathway depends on the completion of PMDA’s assessment of the same clinical trial protocol proposed for the Malaysian application.
Sponsors should consider the following requirements and steps:
Clinical Trial Regulatory Requirements in Japan and Malaysia
Understanding the regulatory context in both countries is essential when planning a reliance-based submission.
- Clinical Trial Regulatory Framework in Japan:
Clinical trials involving investigational medicines in Japan are governed by applicable legislation, including the Pharmaceuticals and Medical Devices Act, and relevant regulations and guidance.
Certain clinical trial notifications are subject to a statutory 30-day investigation. PMDA’s formal acceptance of a notification does not itself constitute permission to conduct a trial. For notifications covered by this requirement, the applicable statutory restrictions must be observed before the relevant trial-related activities can proceed. Sponsors should therefore distinguish completion of the relevant PMDA assessment from a general statement that every Japanese clinical trial notification receives the same 30-day review.
The PMDA clinical trial notification system provides further information on the notification framework.
- Clinical Trial Regulatory Framework in Malaysia:
In Malaysia, the applicable pathway depends on the investigational product and the proposed clinical trial.
A Clinical Trial Import Licence (CTIL) is relevant when an unregistered product is imported for use in a clinical trial. A Clinical Trial Exemption (CTX) applies to the relevant circumstances involving an unregistered product manufactured for clinical trial use. Sponsors must determine the appropriate route and meet NPRA’s current application requirements. Participation in the reliance pilot does not remove the need to submit the required Malaysian application or supporting documentation.
The pilot is specifically intended to support eligible CTIL/CTX applications by allowing NPRA to consider PMDA’s assessment of the corresponding protocol.
Can Regulatory Reliance Accelerate Clinical Trial Review Timelines?
One of the main objectives of the NPRA–PMDA pilot is to explore whether reliance can shorten review timelines by reducing duplicated assessment work. NPRA has stated that it aims to reduce the standard review timeline by half. This is a target being evaluated during the pilot, not a confirmed result or a guaranteed timeline for individual applications.
The actual benefit may depend on factors such as:
- Whether the protocol meets the pilot’s eligibility criteria.
- Whether the required documentation is complete and consistent.
- Whether additional information or clarification is needed.
- The time required for coordination between the sponsor, NPRA and PMDA.
- The regulatory requirements applicable to the specific application.
Sponsors should treat potential time savings as a planning consideration rather than a substitute for realistic submission timelines. A complete, eligible application and early confirmation of requirements remain important.
Who Could Benefit from the Japan–Malaysia Pilot?
The pathway may be relevant to sponsors and organisations planning eligible clinical trials in both Japan and Malaysia.
Potential beneficiaries include:
- Pharmaceutical companies coordinating clinical development across Asian markets.
- Biotechnology companies developing investigational products that may be included within the pilot’s scope.
- Sponsors of multinational clinical trials seeking to reduce avoidable duplication in regulatory assessment.
- Clinical research and regulatory teams managing submission readiness, documentation and cross-border regulatory coordination.
Eligibility must still be assessed against the specific protocol and the pilot’s stated requirements. Sponsors should not assume that every product or clinical trial application involving both countries qualifies.
Challenges and Limitations of the Regulatory Reliance Pathway
Although reliance may improve efficiency, it does not remove all regulatory or operational challenges.
- Protocol alignment: The Malaysian application must use the same protocol that completed PMDA’s relevant assessment. Differences between protocols may make an application ineligible.
- Documentation readiness: Missing forms, incomplete supporting documents or inconsistencies across submission materials can create delays even when the protocol is eligible.
- National requirements: NPRA retains regulatory oversight. Sponsors must continue to address Malaysian requirements and any requests raised during the review.
- Coordination between authorities: The reliance process involves communication between NPRA and PMDA. Sponsors should allow time for the formal request and subsequent review activities.
- Unproven timeline benefits: The pilot is intended to collect evidence on the pathway’s performance. The proposed reduction in review time should not be treated as an established outcome until sufficient data are available.
These considerations make early eligibility checks and coordinate submission planning important for sponsors considering the pathway.
How Can Clinical Trial Sponsors Prepare for the Pilot?
Sponsors can prepare by incorporating reliance eligibility into their clinical regulatory planning rather than considering it only when the Malaysian application is ready.
A practical preparation checklist includes:
- Confirm protocol eligibility: Verify that PMDA’s relevant 30-day assessment is complete and that the Malaysian application will use the same protocol.
- Determine the appropriate Malaysian route: Establish whether CTIL or CTX requirements apply to the proposed trial.
- Check the latest NPRA instructions: Confirm the correct application form, supporting documents, RRR checklist and consent requirements.
- Align submission materials: Review the protocol and supporting documentation for consistency across the Japanese and Malaysian regulatory activities.
- Plan for authority coordination: Allow time for NPRA’s formal request to PMDA and for any follow-up questions.
- Track the pilot’s implementation: Monitor NPRA announcements and guidance for changes to the pathway or clarification of its requirements.
A documented preparation process can help sponsors identify eligibility issues and documentation gaps before submission.
Future Implications for Clinical Trial Regulation in Asia
The NPRA–PMDA pilot represents a practical test of how regulatory authorities can build on one another’s assessment work while retaining national oversight. Its results may help clarify which application types are suitable for reliance, what documentation and coordination are needed, and whether the approach can deliver meaningful improvements in review efficiency.
The findings may also inform future guidance for CTIL/CTX applications and product registrations under the NPRA–PMDA reliance framework. However, any broader application of the approach will depend on the outcomes of the pilot and subsequent regulatory decisions. For sponsors operating across Asian markets, the initiative reinforces the value of monitoring regulatory developments and evaluating new pathways against the requirements of each jurisdiction.
How DDReg Supports Clinical Trial Regulatory Planning
Navigating clinical trial requirements across jurisdictions requires a clear understanding of local pathways, submission documentation and regulatory expectations. DDReg supports sponsors with clinical regulatory planning, regulatory intelligence and regulatory affairs activities to help identify applicable requirements and coordinate submission readiness. By integrating regulatory requirements into clinical development planning early, sponsors can better assess pathway suitability, identify documentation gaps and prepare for cross-border regulatory submissions.
Explore DDReg’s Clinical Regulatory Services, Regulatory Intelligence Services and Regulatory Affairs Services to learn more.
Conclusion
The PMDA–NPRA pilot introduces a defined opportunity to explore clinical trial regulatory reliance in Japan and Malaysia. By allowing NPRA to consider PMDA’s completed assessment of an eligible protocol, the pathway aims to reduce duplicated work while preserving Malaysia’s regulatory oversight.
For sponsors, the key priorities are to confirm protocol eligibility, prepare the required documentation, understand the applicable CTIL/CTX route and monitor NPRA’s evolving guidance. The pilot’s outcomes will be important in determining whether the approach can deliver more efficient review timelines and support a broader reliance framework in the future.
Frequently Asked Questions (FAQs)
Clinical trial regulatory reliance is an approach in which a regulatory authority uses or gives appropriate weight to assessment work completed by another trusted authority when making its own decision. The relying authority retains responsibility for its regulatory decision.
It is a six-month pilot announced by Malaysia’s NPRA and Japan’s PMDA on 21 September 2026, with implementation targeted for October 2026 to March 2027. It explores the use of PMDA assessment inputs to support NPRA’s review of eligible Malaysian CTIL/CTX applications.
The pilot requires the specific clinical trial protocol to have completed PMDA’s standard 30-day assessment process. The same protocol must be used in the Malaysian application. An application submitted before completion of the relevant PMDA assessment, or one using a different protocol, does not meet the stated eligibility criteria.
NPRA has stated that it aims to reduce the standard review timeline by half. This is a target being evaluated during the pilot, not a guaranteed reduction for every application. The actual timeline will depend on the application and the regulatory review process.